Skip to main content
OpenTrials
Completed

NCT Number: NCT05446506

Serum Levels of Otolin-1 and Vitamin D in Pre- and Post-treatments of BPPV

BPPV is the most common cause of vertigo. The pathophysiology of BPPV has not been cleared, several studies show that symptoms are caused by the displacement of otoconia from the macula of the utricle into the semicircular canals. These calcium carbonate particles then stimulate non-physiological movement of the endolymph leading to a false sensation of angular acceleration.

Biomarkers represent measurable products of biological processes, thus making an assessment of those processes more practical. Biomarkers in circulation are powerful indicators of normal and pathological biological processes, as well as, responses to pharmacological treatments. The inner ear-inclusive protein that has been published included Otolin-1, Otoconin-90/95, Prestin, Otoancorin, Otogelin, α-tectorin, β-tectorin and Cochlin.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Otolaryngology Faculty of Medicine, Chiang Mai University 110 Intawaroros Road, Sriphum

Chiang Mai, 50200, Thailand

About this study

The posterior canal BPPV is the most common BPPV variant, diagnosed with the Dix-Hallpike test. The lateral canal BPPV is diagnosed with a supine roll test. After treatment of the posterior canal BPPV with a single cycle of the CRP, the rate of negative DHT was 68-80% in the 1st week. Rate of an absence of vertigo and nystagmus on the supine roll test after-treatment of the lateral canal BPPV with the barbecue maneuver plus forced prolonged positioning was 81%.

Biomarkers are often measured in body fluids, they eliminate the need for costly modalities to diagnose and monitor progression. Otolin-1 is a secreted glycoprotein whose messenger RNA (mRNA) expression is restricted to the inner ear, specifically the support cells of the vestibular maculae, semicircular canal cristae, organ of Corti, and marginal cells of the stria vascularis. Otolin-1 blood levels are significantly higher in patients older than 65 years old and increased prevalence of BPPV with age. There were reports of a relationship between vitamin D and otolin-1. Significantly higher serum levels of the otolin-1 protein in patients with BPPV than in healthy controls has been reported. This also confirmed evidence of the otolin-1 as a potential biomarker for BPPV episodes and maybe clinically used to promote better management of BPPV. No data on inner ear biomarkers has been exited in Thailand.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 - 80 years
  • History of brief episodes of positioning vertigo
  • Positive positioning test; either Dix-Hallpike test or supine roll test in one or both ears
  • First diagnosis of BPPV or recurrent BPPV

Exclusion criteria

  • Clinical symptoms or sign of other central or peripheral vestibular disorder
  • Previous history of balance disorders (for controlled group) or Previous history of balance disorders except BPPV (for BPPV group)
  • Active infection
  • Active cancer disease
  • Conditions that may affect the level of otolin-1 such as previous mastoidectomy
  • Conditions that may affect the level of vitamin D such as cardiovascular disease, diabetes mellitus type2, chronic liver disease, osteoporosis osteomalacia and active symptoms of migraine
  • Major health conditions; except common chronic conditions e.g. hypertension, hypothyroidism, hypercholesterolemia, and reflux
  • Major systemic illness, were undergoing active cancer treatment, took prednisone above 10 mg daily, took other immunosuppressive drugs, took any medications for rheumatoid arthritis other than NSAIDs, or had received antibiotics in the previous 6 months
  • Unable to complete Thai-Dizziness handicap inventory questionnaire
  • Unable to obtain the blood specimen

Treatment and study plan

Primary outcomes

  1. Level of serum otolin-1 and vitamin D

    Time frame: Day 0 and 7±3days after treatment

    changes of Level of serum otolin-1 and vitamin D before and after treatment of BPPV

Secondary outcomes

  1. Correlation of serum otolin-1 and vitamin D

    Time frame: Day 0 and 7±3days after treatment

    Correlation of serum otolin-1 and vitamin D before and after treatment period in BPPV patients

Sponsors and collaborators

Lead sponsor

Chiang Mai University

Other

Registry information

Official study title

Comparative Study for Serum Levels of Otolin-1 and Vitamin D in pre-and Post-treatments of Patients With Benign Paroxysmal Positional Vertigo

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Jul 6, 2022
Registry last updated
Aug 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.